Pulmonx Corp
No enriched coverage for $LUNG in the last 7 days.
No SEC Form 4 filings for $LUNG in the last 30 days.
Pulmonx Corp (LUNG) reported its Q1 2026 results, surpassing revenue and EPS estimates with $20.6 million in revenue and a GAAP EPS of -$0.33. Despite a 9% year-over-year revenue decline, the company saw gross margin expand to 78% and attributed international declines to a temporary registration pause in China. GuruFocus considers LUNG 85.3% undervalued, trading at a significant discount to its intrinsic value.
Pulmonx Corp (LUNG) has reaffirmed its 2026 revenue guidance, projecting between $90 million and $92 million, with a robust gross margin near 75%. Despite anticipated operating expenses between $113 million and $115 million, the company, which specializes in minimally invasive treatments for severe emphysema, shows strength in growth but has concerns regarding profitability and financial stability. Its GF Score™ of 59 and a low price-to-sales ratio of 0.55 suggest potential undervaluation, though caution is advised due to insider selling and financial health indicators.
Pulmonx (LUNG) reported mixed financial results for Q1 2026, with an EPS of -$0.33, beating estimates, but revenue of $20.6 million, missing forecasts. The stock dropped 0.81% in aftermarket trading, nearing its 52-week low, due to investor concerns over the revenue miss and continued net losses. Despite the challenges, the company is focused on re-accelerating U.S. sales, advancing its AeriSeal program to expand its market, and aligning its cost structure for profitability, with management expressing confidence in returning to double-digit growth by year-end.
